The sodium oxybate REMS program: greed isn't good.

  • Published In: Brown University Psychopharmacology Update, 2023, v. 34, n. 7. P. 7 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Price, Lawrence H. 3 of 3

Abstract

Back in November 2020, a point in our history that you may recall as marked by, one could say, "disquiet," I wrote a commentary addressing an issue of pharmacoeconomics pertaining to our field (Price, 2020). I acknowledged at the time some trepidation about departing from our core mission of covering psychopharmacology, but argued that the specific topic (dramatic disparities in the pricing of generic psychiatric drugs) was of such great importance to us as psychiatric providers that the exception was justified. Now, nearly three years later, I find myself again sufficiently roiled to make a similar exception. [ABSTRACT FROM AUTHOR]

Additional Information

  • Source:Brown University Psychopharmacology Update. 2023/07, Vol. 34, Issue 7, p7
  • Document Type:Article
  • Subject Area:Religion and Philosophy
  • Publication Date:2023
  • ISSN:1068-5308
  • DOI:10.1002/pu.31037
  • Accession Number:163950132
  • Copyright Statement:Copyright of Brown University Psychopharmacology Update is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.